DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T‑DM1 resistance - Takegawa, N; Nonagase, Y; Yonesaka, K (Int J Cancer, 2017)
et al.